| A Multi-Center Study to Evaluate the Efficacy and Safety of KX01 Ointment 1% on Actinic Keratosis on Face or Scalp (NCT05231044) | PharmaEssentia | 2021-12-21 |
| Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp (NCT05060237) | Biofrontera Bioscience GmbH | 2021-12-01 |
| Pain Management During a Photodynamic Therapy Session on the Vertex for Actinic Keratosis: Tumescent Anesthesia Interest (NCT04779255) | Poitiers University Hospital | 2021-07-28 |
| Daylight Photodynamic Therapy for the Treatment of Actinic Keratoses in the Northeast United States (NCT02867722) | Brigham and Women's Hospital | 2020-12-01 |
| 5% KOH Solution vs. Placebo and Diclofenac Gel for the Treatment of Actinic Keratosis (NCT04552327) | Infectopharm Arzneimittel GmbH | 2020-10-14 |
| Conventional Photodynamic Therapy vs. Painless Photodynamic Therapy for Actinic Keratosis (NCT04396184) | Shanghai Dermatology Hospital | 2020-05-01 |
| Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses (NCT04140292) | Case Comprehensive Cancer Center | 2020-01-13 |
| Indoor Daylight Photo Dynamic Therapy for Actinic Keratosis (NCT03805737) | Dartmouth-Hitchcock Medical Center | 2019-11-01 |
| Photodynamic Therapy-Induced Immune Modulation: Part III (NCT03643744) | Wright State University | 2019-04-01 |
| Menthol for PDT Pain Relief (NCT02984072) | University of Dundee | 2018-10-23 |
| Topical Ionic Contra-Viral Therapy in Actinic Keratosis (NCT03684772) | Maruho Co., Ltd. | 2018-10-22 |
| Study to Evaluate the Efficacy, Safety, and Tolerability of Topical VDA-1102 Ointment in Subjects With Actinic Keratosis (NCT03538951) | Vidac Pharma | 2018-05-23 |
| Biomarker Database Registry for Photodynamic Therapy (NCT03319251) | The Cleveland Clinic | 2017-10-06 |
| A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004) (NCT03285490) | Almirall, S.A. | 2017-09-15 |
| A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp (NCT03115476) | LEO Pharma | 2017-06-16 |
| Safety and Efficacy Study of AM001 Cream in the Treatment of Actinic Keratosis (NCT03210740) | AmDerma | 2017-06-06 |
| Study of SOR007 Ointment for Actinic Keratosis (NCT03083470) | DFB Soria, LLC | 2017-05-18 |
| Efficacy of Ingenol Mebutate on Actinic Keratoses and Field Cancerization vs Cryotherapy (NCT02990221) | University of Campania Luigi Vanvitelli | 2017-04-12 |
| Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp (NCT03024060) | DUSA Pharmaceuticals, Inc. | 2017-03-01 |
| Efficacy of Ablative Fractional Laser-assisted Photodynamic Therapy According to the Laser Density for Actinic Keratosis (NCT03731988) | Dong-A University | 2017-02-01 |
| Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide (NCT03122457) | Icahn School of Medicine at Mount Sinai | 2017-01-01 |
| Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients (NCT02866695) | University of California, San Francisco | 2016-10-06 |
| Potential Impact of Patient Vitamin D Status in AK Response to MAL-PDT (NCT02878382) | University of Sao Paulo | 2016-10-01 |
| Pilot Study of the Pragmatic Use of Mobile Phone Based Follow up of Actinic Keratoses Treated With Topical 5-fluorouracil (NCT02938715) | University of California, Davis | 2016-10-01 |
| Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo (NCT02902822) | Centro Studi Gised | 2016-10-01 |
| Daylight Photodynamic Therapy for Actinic Keratosis and Skin Field Cancerization (NCT03013647) | University of Sao Paulo General Hospital | 2016-09-01 |
| An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis (NCT03200912) | Actavis Inc. | 2016-08-19 |
| Laser and Microdermabrasion Before Photodynamic Therapy for Actinic Keratoses in Field-cancerized Skin (NCT03006185) | Bispebjerg Hospital | 2016-08-01 |
| Efficacy and Safety of VDA-1102 Ointment in the Treatment of Actinic Keratosis (NCT02844777) | Vidac Pharma | 2016-07-15 |
| Biological Effects of LEO 43204 in Actinic Keratosis (NCT02600598) | LEO Pharma | 2016-07-01 |
| Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp (NCT02838628) | Almirall, S.A. | 2016-04-11 |
| Microneedle Lesion Preparation Prior to Aminolevulinic Acid Photodynamic Therapy (ALA-PDT) for AK on Face (NCT02632110) | DUSA Pharmaceuticals, Inc. | 2016-03-01 |
| A Clinical Study to Evaluate the Sensitizing Potential of LEO 43204 Gel (NCT02650505) | LEO Pharma | 2016-02-01 |
| Using a Cold Atmospheric Plasma Device to Treat Skin Disorders (NCT02759900) | The Skin Center Dermatology Group | 2016-01-01 |
| The Use of Picato® (Ingenol Mebutate) to Treat Actinic Keratosis in Standard Clinical Practice (NCT02594436) | LEO Pharma | 2015-12-01 |
| Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between MAL Cream and ALA Gel (NCT02647151) | Fundación Instituto Valenciano de Oncología | 2015-12-01 |
| Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up (NCT02549339) | LEO Pharma | 2015-11-13 |
| Clinical and Histologic Evaluation of Picato 0.15% Gel in the Cosmetic Improvement of Photoaged Skin (NCT03508856) | Skin Laser & Surgery Specialists | 2015-11-09 |
| Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up (NCT02547233) | LEO Pharma | 2015-11-01 |
| Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up (NCT02549352) | LEO Pharma | 2015-11-01 |
| Multiple-dose Pharmacokinetic Study of Solamargine in Patients With Actinic Keratosis (NCT02559934) | G&E Herbal Biotechnology Co., LTD | 2015-11-01 |
| Eight Week Study of Treatment With DFD-07 for Actinic Keratosis of the Face and Scalp (NCT02654717) | Promius Pharma, LLC | 2015-11-01 |
| Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up (NCT02547363) | LEO Pharma | 2015-11-01 |
| A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp (NCT02611804) | Teva Pharmaceuticals USA | 2015-10-01 |
| Metvix Daylight PDT in Actinic Keratosis (NCT02674048) | Galderma R&D | 2015-09-01 |
| Ingenol Mebutate Gel 0.05% in Kidney Transplant Recipients With Actinic Keratoses (NCT02473848) | Günther Hofbauer | 2015-06-01 |
| Daylight PDT for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL) (NCT02464709) | Joint Authority for Päijät-Häme Social and Health Care | 2015-06-01 |
| To Compare Safety and Efficacy of Perrigo's Drug Compared to an FDA Approved Drug in the Treatment of Actinic Keratosis (NCT02459795) | Padagis LLC | 2015-05-01 |
| Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions (NCT02424305) | LEO Pharma | 2015-05-01 |
| Clinical Trial of Ingenol Mebutate Gel 0.015% & 0.05% in Actinic Keratosis (NCT02716714) | Korea University | 2015-04-01 |
| Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses (NCT03327831) | University of California, Irvine | 2015-04-01 |
| Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest (NCT02361216) | LEO Pharma | 2015-04-01 |
| Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients (NCT02404389) | Novartis Pharmaceuticals | 2015-03-05 |
| Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively (NCT02305888) | LEO Pharma | 2015-03-01 |
| Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis (NCT02616601) | Actavis Inc. | 2015-02-27 |
| A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis (NCT02654769) | Actavis Inc. | 2015-02-01 |
| To Compare Safety and Efficacy of Perrigo's Drug Product Compared to an FDA Approved Drug Product in the Treatment of Actinic Keratosis (NCT02385318) | Padagis LLC | 2015-02-01 |
| Ingenol Mebutate (Picato®) With Methyl Aminolevulinate Photodynamic Therapy for the Treatment of Actinic Keratosis (NCT02354391) | Pacific Dermaesthetics | 2015-01-01 |
| Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015% (NCT02446223) | Goldman, Butterwick, Fitzpatrick and Groff | 2015-01-01 |
| Ph 1, Single-Center, Safety, Tolerability & Pharmacokinetic Study of KX2 391 Ointment in Subj. w Actinic Keratosis (NCT02337205) | Athenex, Inc. | 2014-12-01 |
| Open Uncontrolled Validation Study for the German Version of the Actinic Keratosis Quality of Life Questionnaire (AKQoL) (NCT02325661) | University of Zurich | 2014-10-01 |
| Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In Patients With Grade I-II Actinic Keratoses (NCT02289768) | Almirall, S.A. | 2014-10-01 |
| PMS to Evaluate the Safety and Efficacy of Picato® Gel (NCT02421471) | LEO Pharma | 2014-09-01 |
| Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (ALA) Photodynamic Therapy (NCT02239679) | DUSA Pharmaceuticals, Inc. | 2014-09-01 |
| Twelve Month Follow-Up of CP0108 (NCT02209012) | DUSA Pharmaceuticals, Inc. | 2014-08-01 |
| Treatment of Field Cancerization for Reduction in Tumor Burden - A Prospective Study (NCT02150863) | Massachusetts General Hospital | 2014-08-01 |
| The Real Life Topical Field Treatment of Actinic Keratosis Study (NCT02362152) | LEO Pharma | 2014-07-01 |
| Efficacy of Iontophoresis-assisted AFL-PDT in Actinic Keratosis (NCT02670655) | Dong-A University | 2014-06-01 |
| Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities (NCT02137785) | DUSA Pharmaceuticals, Inc. | 2014-05-01 |
| Safety and Tolerability Study of Ingenol Mebutate Compared to 5-FU to Treat Facial Actinic Keratosis (NCT02242747) | University of Sao Paulo | 2014-05-01 |
| Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis (NCT02120456) | LEO Pharma | 2014-05-01 |
| Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis (NCT02100813) | LEO Pharma | 2014-05-01 |
| TreatMent of ActInic KerAtosis Lesions : pharmacoepiDemiological Study of the Impact in Real Life of ingenOl Mebutate Gel (Picato®) on Patients Satisfaction (NCT04202445) | LEO Pharma | 2014-04-01 |
| Protocols for Painless Photodynamic Therapy (PDT) of Actinic Keratoses (NCT02124733) | The Cleveland Clinic | 2014-04-01 |
| ACT01 in Combination With Comp01-04 in Patients With Actinic Keratosis (NCT02126670) | Promius Pharma, LLC | 2014-04-01 |
| Pharmacokinetics of Ingenol Mebutate Gel in Actinic Keratosis Under Maximum Use Conditions (NCT02124239) | LEO Pharma | 2014-04-01 |
| Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis (NCT01998984) | LEO Pharma | 2014-01-01 |
| Pharmacokinetic Study of Solamargine in Patients With Actinic Keratosis (NCT02029066) | G&E Herbal Biotechnology Co., LTD | 2013-11-01 |
| A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses (NCT02120898) | Actavis Inc. | 2013-10-10 |
| A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis (NCT01922050) | LEO Pharma | 2013-10-01 |
| Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT) (NCT01966120) | Biofrontera Bioscience GmbH | 2013-10-01 |
| Actinic Keratosis Study (NCT02019355) | Washington University School of Medicine | 2013-10-01 |
| Nanocytology Test to Evaluate Skin Cancer in High Risk Patients (NCT01905891) | Northwestern University | 2013-07-01 |
| Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate in a Period of 8 Weeks (NCT02090465) | LEO Pharma | 2013-07-01 |
| Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05% (NCT01892137) | LEO Pharma | 2013-07-01 |
| Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis (NCT01820260) | LEO Pharma | 2013-04-01 |
| A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic Keratosis (NCT01962987) | Actavis Inc. | 2013-03-01 |
| Safety and Dose Finding Study of New Vehicle Formulations Containing Ingenol Mebutate to Treat Actinic Keratosis on the Forearm (NCT01803477) | LEO Pharma | 2013-02-01 |
| Efficacy and Safety Phase II Study of SR-T100 to Treat Actinic Keratosis (NCT01516515) | G&E Herbal Biotechnology Co., LTD | 2013-02-01 |
| A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities (NCT01787383) | LEO Pharma | 2013-02-01 |
| Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis. (NCT01788007) | Sun Pharmaceutical Industries, Inc. | 2013-01-01 |
| Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream (NCT03914417) | Icahn School of Medicine at Mount Sinai | 2013-01-01 |
| Safety and Tolerability of Different Concentrations of an Ingenol Derivative Field Therapy in the Treatment of Actinic Keratosis (NCT01703078) | LEO Pharma | 2012-11-01 |
| Ingenol Mebutate Compared to Cryotherapy for the Treatment of Skin Lesions (NCT01735942) | Northwestern University | 2012-10-01 |
| A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® Gel 3% in the Treatment of Actinic Keratosis (NCT01742663) | Sun Pharmaceutical Industries, Inc. | 2012-10-01 |
| Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis (NCT01686152) | Teva Pharmaceuticals USA | 2012-09-01 |
| The Use of Microneedles in Photodynamic Therapy (NCT01812837) | University of California, Davis | 2012-07-01 |
| Long Term Efficacy and Safety of Eryfotona AK-NMSC® in Patients With Actinic Keratosis (NCT01656226) | ISDIN | 2012-07-01 |
| Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp (NCT01600014) | LEO Pharma | 2012-05-01 |
| Dose-finding, Safety, Efficacy Trial of Topical Resiquimod in Patients With Multiple Actinic Keratosis Lesions (NCT01583816) | Spirig Pharma Ltd. | 2012-05-01 |